Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CheckMate 274 at ESMO 2025: Adjuvant Nivolumab in MIBC
ASCO GU 2023: Extended Follow-up Results from the CheckMate 274 Trial
Figure 2, CheckMate 274 Study Design Schematic - Nivolumab (Opdivo ...
EAU 2024: Extended Follow-up from CheckMate 274 Including the First ...
ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of ...
Checkmate 274 Adjuvant Nivolumab in Urothelial Cancer | An Oncologist's ...
(PDF) Checkmate 274 trial: Is Nivolumab the new standard in adjuvant ...
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC ...
CheckMate 274 follow up data boost nivolumab potential for high-risk ...
Updated CheckMate 274 Data Reaffirm Benefit of Adjuvant Nivolumab in ...
First results from the phase 3 CheckMate 274 trial of adjuvant ...
CheckMate 274 Adjuvant Nivolumab May Improve Disease-Free Survival in ...
CheckMate 274: Nivolumab adyuvante en carcinoma urotelial invasivo de ...
CheckMate 274: resultados estendidos do uso de nivolumabe para o ...
CheckMate 274: Adjuvant Treatment With Nivolumab for Patients With MIUC ...
CheckMate 274: Nivolumab Boosts Survival in High-Risk Urothelial Cancer
CheckMate 274: 5-year data confirm durable benefit with nivolumab ...
CheckMate 274: additional survival outcomes of adjuvant nivolumab in ...
Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus ...
CheckMate 274: adjuvant nivolumab versus placebo for urothelial ...
CheckMate 274: nivolumab versus placebo in high-risk urothelial cancer ...
OPDIVO® (nivolumab) for the Adjuvant Treatment of High-Risk Urothelial ...
Adjuvant nivolumab improves disease-free survival in patients with ...
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in ...
ASCO GU 2025: Adjuvant Nivolumab vs Placebo for High-Risk Muscle ...
Nivolumab CheckMate-274 Extended Results ASCO GU 2025 Continued Benefit ...
ESMO 2022: Tumor and Immune Features Associated with Disease-Free ...
Extended CheckMate-274 Data Reinforce the Benefit of Adjuvant Nivolumab ...
ESMO 2025: Adjuvant Nivolumab versus Placebo for High-Risk Muscle ...
Health-related Quality of Life with Adjuvant Nivolumab After Radical ...
VÑ CheckMate-274, Cá Urotelial-inv, ady [Nivolumab] vs [Placebo] - YouTube
CheckMate-274 Analysis Explores Role of Adjuvant Nivolumab in High-Risk ...
Nivolumabe adjuvante no câncer de bexiga músculo-invasivo: atualizações ...
EAU 2021: Health-Related Quality of Life with Adjuvant Nivolumab v ...
Following Checkmate-274 trial, FDA approves adjuvant Nivolumab for high ...
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma ...
Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC ...
Adjuvant nivolumab versus placebo for high-risk muscle-invasive ...
Early-stage multi-cancer detection using an extracellular vesicle ...
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
ニボルマブの尿路上皮がんアジュバント、DFS改善（CheckMate-274）／BMS｜医師向け医療ニュースはケアネット
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory ...
Society of Urologic Oncology - DISEASE-FREE SURVIVAL WITH LONGER FOLLOW ...
(PDF) Adjuvant nivolumab versus placebo following radical surgery for ...
ASCO 2025: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
